{"id":41638,"date":"2019-03-21T12:09:21","date_gmt":"2019-03-21T11:09:21","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=41638"},"modified":"2019-03-21T12:25:27","modified_gmt":"2019-03-21T11:25:27","slug":"top-15-dei-farmaci-piu-venduti-al-mondo","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/top-15-dei-farmaci-piu-venduti-al-mondo\/","title":{"rendered":"Top 15 best-selling drugs in the world"},"content":{"rendered":"

A study published in January by the IQVIA Institute for Human Data Science reports that worldwide drug spending reached $ 1.2 trillion (1.2 trillion) in 2018 and will exceed $ 1.5 trillion by 2023, according to \u201cGlobal Drug Use in 2019 and Outlook to 2023<\/a>”
\n<\/span><\/p>\n

Below is the updated overall top 15 of best-selling prescription drugs. The drug that topped the best-seller list in 2017 also topped the overall drug best-seller list in 2013, when it generated $10.659 billion, a jump of 87% in five years.<\/span><\/p>\n

\"\"<\/a>Top-selling drugs are ranked by 2018 sales or revenue reported by biopharmaceutical companies in press releases, annual reports, investor materials, and\/or conference calls. Each drug is listed by name, sponsor(s), indicated diseases, 2018 sales, 2017 sales, and the percentage change between both years.<\/span><\/p>\n

Ten of last year's 15 best-selling drugs had year-over-year sales gains, while six of the 10 were double-digit increases. The rest of the list has seen declines in sales since 2017, most often reflecting the launch of generic competitors or discounts from insurers.<\/span><\/p>\n

Those ranked 20th to 16th are treatments that generated between $ 4 billion and approximately $ 4.7 billion last year: Sanofi's Lantus\u00ae (insulin glargine), Pfizer's Ibrance\u00ae (palbociclib), Tecfidera\u00ae biogen (dimethyl fumarate), Gilead Sciences' Genvoya\u00ae (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide); and Amgen\/Kyowa Hakko Kirin's Neulasta\u00ae\/Peglasta\u00ae (pegfilgrastim), which cracked last year's Top 15.<\/span><\/p>\n

This year, cancer continues to be the most expensive major disease category with 6 of the 15 best-selling drugs, including 3 of the top 5, while arthritis grew to 5th (up from 4th last year) such as Stelara from Janssen Biotech (Johnson & Johnson) \u00ae (ustekinumab). Also this year it is Merck & Co.'s Keytruda\u00ae (pembrolizumab) again, which ranks in the top 5.<\/span><\/p>\n

JAN<\/a><\/strong> By \u2013 Alex Philippidis<\/a> –

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

References<\/em>
\n1. Pfizer lists separately the Lyrica revenues generated in all of Europe, Russia, Turkey, Israel, and Central Asia countries ($347 million in 2018, $553 million in 2017). Those revenues are listed by Pfizer's \u201cEssential Health\u201d operating segment, while its \u201cInnovative Health\u201d segment records Lyrica revenues generated elsewhere in the world, including the US ($4.622 billion in 2018, $4.511 billion in 2017).<\/em>
\n2. Biogen receives a share of US pre-tax profits on sales of Rituxan, which is marketed by Genentech (Roche). Sales figures do not include US pre-tax profits generated by Biogen, since the company only discloses those profits combined with profits from Gazyva\u00ae (obinutuzumab), and does not break out each product separately. Biogen reported combined Rituxan-Gazyva pre-tax profits of $1.432 billion for 2018, and $1.316 billion for 2017.<\/em>
\n3. Pfizer markets Enbrel outside the US and Canada, where the treatment is marketed by Amgen.<\/em>
\n4. Pfizer figures for Eliquis consist of \u201calliance revenues\u201d reflecting products co-developed with partner companies, as well as direct sales in some regions of the world.<\/em><\/p>\n

Related news: Top 10 cele mai mari companii pharmaceutical din lume. Pe primul loc, o firma americana cu venituri de peste 50 billion dollars<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Uno studio pubblicato a gennaio dall’IQVIA Institute for Human Data Science riferisce che la spesa mondiale per i farmaci ha raggiunto $ 1,2 trilioni (1,2milamiliardi) nel 2018 e superer\u00e0 $ 1,5 trilioni entro il 2023, secondo “L’uso globale dei farmaci nel 2019 e Outlook al 2023” Di seguito \u00e8 riportata la top 15 generale aggiornata …<\/p>","protected":false},"author":4,"featured_media":41645,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[26],"class_list":["post-41638","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/41638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=41638"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/41638\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/41645"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=41638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=41638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=41638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}